

## Elenco Oral Communications

ID	Title	Presenting Author
<b>13/10/2020 16.00 - 17.00 Social Science</b>		
<b>125</b> OC 1 16.00-16.10	Awareness and perception of accuracy of the U = U message in people living with HIV (PLWHIV), in Italy and correlation with the level of confidence in reference physicians	Antonella Cingolani, Roma
<b>341</b> OC 2 16.10-16.20	Hepatitis C, HIV and Tuberculosis among vulnerable populations in an out-of-hospital setting: a seroprevalence analysis from "The week of the poor" experience	Giuseppe De Simone, Roma
<b>42</b> OC 3 16.20-16.30	Engagement of younger generations in the fight against HIV/AIDS	Paolo Meli, Bergamo
<b>238</b> OC 4 16.30-16.40	Post-migration HIV infection in the foreign-born population enrolled in the ICONA cohort	Annalisa Saracino, Bari
<b>256</b> OC 5 16.40-16.50	BLQ Checkpoint: characteristics of users and services offered. A 5 years review	Giulio Maria Corbelli, Roma
<b>293</b> OC 6 16.50-17.00	Sexual behaviour and associated risk for sexual health among men who have sex with men (MSM) in Italy: data from the EMIS 2017 survey	Michele Breveglieri, Bologna
<b>13/10/2020 17.30 - 18.30 Antiretroviral Therapy</b>		
<b>122</b> OC 7 17.30-17.40	Durability of dolutegravir-based regimens after the first year of therapy	Lucia Taramasso, Milano
<b>39</b> OC 8 17.40-17.50	Switch to RPV+DRV/cobi: 48week results of the PROBE 2 study	Franco Maggiolo, Bergamo
<b>131</b> OC 9 17.50-18.00	Predictors of virological failure among HIV-1 infected patients switching from an effective first line antiretroviral regimen. A preliminary analysis	Laura Magnasco, Genova
<b>38</b> OC 10 18.00-18.10	Long term efficacy of dolutegravir + lamivudine as simplification cART in patients with suppressed HIV-RNA	Franco Maggiolo, Bergamo
<b>109</b> OC 11 18.10-18.20	Lamivudine+dolutegravir (3TC+DTG) switch strategy compared with the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in virologically suppressed HIV patients: preliminary results from an Italian center	Gianmaria Baldin, Olbia
<b>283</b> OC 12 18.20-18.30	Durability of F/TAF regimens in the era of integrase inhibitors in a large cohort of PLWH seen for care in Italy	Alessandra Vergori, Roma
<b>13/10/2020 18.30 - 19.30 HIV Prevention</b>		
<b>308</b> OC 13 18.30-18.40	Engagement, adherence and rate of discontinuation in an Italian access program of HIV pre-exposure prophylaxis (ItaPrEP)	Valentina Mazzotta, Roma
<b>299</b> OC 14 18.40-18.50	Pre-Exposure Prophylaxis (PrEP) use at five Infectious Diseases Units in northern Italy (PrEP-Italy study)	Serena Venturelli, Bergamo
<b>345</b> OC 15 18.50-19.00	Uptake and effects on sexual behaviour in a cohort of PrEP users	Pietro Leone Giovanni Vinti, Milano
<b>349</b> OC 16 19.00-19.10	Preventive measures against HIV and sexually transmitted infections among key populations referring to a counseling and testing center in the metropolitan area of Rome	Rozenn Esvan, Roma
<b>269</b> OC 17 19.10-19.20	Incidence of STIs and HIV in a cohort of MSM and MtF with high prevalence of risk factors for HIV acquisition evaluated in a PrEP community-based service in Italy: one-year follow-up data from SEX-CHECK study	Diletta Testi, Firenze
<b>221</b> OC 18 19.20-19.30	HIV and motherhood – A survey on women's experiences in the U=U era	Maria Grazia Di Benedetto, Como
<b>14/10/2020 15.00 - 16.00 Virology</b>		
<b>99</b> OC 19 15.00-15.10	Defining stable reference genes to analyze cell associated HIV RNA induced by latency reversing agents	Cristina Ceriani, Chapel Hill, USA
<b>272</b> OC 20 15.10-15.20	Prevalence of drug resistance mutations to rilpivirine and doravirine among NNRTI - experienced patients in Italy: a cross-sectional study	Alessandro Lazzaro, Torino

## Elenco Oral Communications

ID	Title	Presenting Author
251 15.20-15.30	<b>OC 21</b> HIV-DNA from rectal GALT is a valid marker to characterize the viral reservoir	Christof Stingone, Roma
67 15.30-15.40	<b>OC 22</b> Evaluation of HIV-1 tropism in multidrug-resistant cART failing patients	Yagai Bouba, Roma
262 15.40-15.50	<b>OC 23</b> Does dual therapy have an impact on HIV-DNA decay in virologically-suppressed patients compared to triple therapy? Results from a multicentric study	Arianna Emiliozzi, Siena
77 15.50-16.00	<b>OC 24</b> Prevalence of high-risk HPV genotypes and HPV genotypes targeted by the nine-valent vaccine Gardasil-9 and the associated risk factors	Elena Bruzzesi, Modena
<b>14/10/2020 17.30 - 18.30 Comorbidities</b>		
296 17.30-17.40	<b>OC 25</b> Fat distribution and density in PLWH with $\geq 5\%$ weight gain	Marianna Menozzi, Modena
1 17.40-17.50	<b>OC 26</b> Statin Eligibility in People living with HIV: are we using the right tools to identify patients at risk of developing major cardiovascular disease?	Maria Mazzitelli, Catanzaro
93 17.50-18.00	<b>OC 27</b> Prevalence, predictors and evolution of lean non-alcoholic fatty liver disease in HIV mono-infected patients	Adriana Cervo, Palermo
355 18.00-18.10	<b>OC 28</b> NAFLD with significant fibrosis in PLWH informs the natural history of cardiovascular disease	Jovana Milic, Modena
26 18.10-18.20	<b>OC 29</b> Decline of metabolic syndrome and increase in overweight in HIV infected patients from 2005-2015	Lucia Taramasso, Milano
328 18.20-18.30	<b>OC 30</b> Progression of anal/cervical dysplasia is associated with Human Papillomavirus (HPV) and Syphilis coinfection in HIV-infected patients	Camilla Tincati, Milano
<b>14/10/2020 18.30 - 19.30 Clinical Hepatitis and coinfections</b>		
229 18.30-18.40	<b>OC 31</b> The contribution of late presentation and late ART initiation to TB-HIV occurrence across four countries	Enrico Girardi, Roma
66 18.40-18.50	<b>OC 32</b> HPV 16 and 18 infections contribute to development of anal cytological abnormalities in a cohort of PLWH	Nicola Squillace, Monza
213 18.50-19.00	<b>OC 33</b> Impact of syphilis on the risk of HIV viral rebound in HIV positive patients under effective antiretroviral treatment: data from the ICONA cohort	Andrea Giacomelli, Milano
300 19.00-19.10	<b>OC 34</b> Decrease of prevalence of subjects harboring replicating HCV among PLWHIV in Italy: results from the NoCo study	Antonella d'Arminio Monforte, Milano
164 19.10-19.20	<b>OC 35</b> Innovative procedures for micro-elimination of HCV infection in a high-risk population of undocumented migrants and low-income refugees	Margherita Macera, Napoli
307 19.20-19.30	<b>OC 36</b> HCV treatment and reinfection risk in injecting drug users in Residential Treatment Setting for drug addiction. San Patrignano HCV-free	Antonio Boschini, Rimini
<b>15/10/2020 15.20 - 16.20 Basic science and immunology</b>		
121 15.20-15.30	<b>OC 37</b> Reduced probability of achieving optimal viro-immunological condition in subjects with vertical transmission of HIV reaching adult age with unsuppressed HIV RNA or incomplete immunological recovery	Anna Celotti, Brescia
36 15.30-15.40	<b>OC 38</b> Immunological recovery in T-cell activation after DAA treatment and SVR in HIV positive subjects with chronic hepatitis C	Franco Maggiolo, Bergamo
172 15.40-15.50	<b>OC 39</b> Higher frequency of CD4+PD1+ T cells and Interferon-Stimulate Genes are associated to a decrease in CD4+ Treg levels in HIV-1 infected patients	Federica Frasca, Roma
30 15.50-16.00	<b>OC 40</b> Macrophage transcriptome profiling upon CCL2 neutralization identifies an association between activation of antiviral responses and HIV-1 restriction	Laura Fantuzzi, Roma
310 16.00-16.10	<b>OC 41</b> High frequency of Myeloid Derived Suppressor Cells in Immunological Non Responders: possible involvement in CD4 T cell recovery	Alessandra Sacchi, Roma

## Elenco Oral Communications

ID	Title	Presenting Author
<b>126</b> OC 42	HIV-binding specificity and -neutralizing potency after ART interruption in chronically HIV-1 infected subjects with long-lasting virological suppression (APACHE study).	Gabriel Siracusano, Milano
16.10-16.20		
<b>15/10/2020</b>	<b>17.20 - 18.20</b>	<b>Clinical HIV</b>
<b>317</b> OC 43	Machine learning statistical approach to identify HIV co-infected patients with asymptomatic neurosyphilis	Luigi Celani, Roma
17.20-17.30		
<b>231</b> OC 44	Body composition changes in HIV: do INSTI matter?	Jovana Milic, Modena
17.30-17.40		
<b>86</b> OC 45	Risk of weight gain (WG) according to type of switching strategy in a large cohort of HIV-infected individuals with stable suppressed HIV-RNA	Stefania Cicalini, Roma
17.40-17.50		
<b>306</b> OC 46	Impact of antiretroviral therapy on gut CD4 T cells activation: differences between naïve and long-term treated HIV-1 infected patients	Giuseppe Pietro Innocenti, Roma
17.50-18.00		
<b>150</b> OC 47	Residual Inflammation and CD4/CD8 Recovery After Switching to Dual Therapy	Stefania Cannizzo, Milano
18.00-18.10		
<b>228</b> OC 48	Evaluation of the impact of resistance on virological efficacy of STR regimens and emergence of resistance at virological failure	Giulia Stella, Arezzo
18.10-18.20		
<b>16/10/2020</b>	<b>15.20 - 16.20</b>	<b>Special Session on HIV and COVID in Italy</b>
<b>390</b> OC 49	SARS-CoV-2 infection in PLWHIV: a large single center cohort	Franco Maggiolo, Bergamo
15.20-15.30		
<b>392</b> OC 50	Newly diagnosed HIV infections at a Counseling and Testing Service during COVID-19 pandemic	Francesca Gili, Roma
15.30-15.40		
<b>394</b> OC 51	HIV and SARS-CoV-2 co-infection: epidemiological, clinical and immunological aspects among HIV-positive young individuals	Claudia Vanetti, Milano
15.40-15.50		
<b>378</b> OC 52	Clinical features and outcomes of HIV patients with coronavirus disease 2019	Cristina Gervasoni, Milano
15.50-16.00		
<b>382</b> OC 53	Antibody responses to SARS -CoV-2 in people living with HIV (PLWH) in Umbria	Chiara Papalini, Perugia
16.00-16.10		
<b>16/10/2020</b>	<b>15.20 - 15.50</b>	<b>Immunopathogenesis</b>
<b>327</b> OC 54	Psycosexual health and systemic, mucosal immune activation and in hiv-infected ART suppressed and uninfected women: evaluation of biomarkers and environmental stimuli	Parni Nijhawan, Roma
15.20-15.30		
<b>182</b> OC 55	Inflammatory burden in people living with four-class drug resistant HIV: data from the PRESTIGIO registry	Tommaso Clemente, Milano
15.30-15.40		
<b>223</b> OC 56	Gut microbial dysbiosis is linked to immune-reconstitution and CD4+ T-cell skewing in MSM with high Framingham Risk Score	Giuseppe Ancona, Milano
15.40-15.50		
<b>16/10/2020</b>	<b>15.50 - 16.20</b>	<b>Hepatitis and clinical virology</b>
<b>331</b> OC 57	Unexpected rising in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies	Lorenzo Piermatteo, Roma
15.50-16.00		
<b>80</b> OC 58	HCV genetic variability in patients with related hepatocellular carcinoma	Alessandra Di Fraia, Napoli
16.00-16.10		
<b>334</b> OC 59	Prevalence and Resistance Analysis of "Unusual" Hepatitis C Virus (HCV) Subtypes within the Italian Resistance Network VIRONET-C	Velia Chiara Di Maio, Roma
16.10-16.20		
<b>16/10/2020</b>	<b>16.20 - 17.20</b>	<b>Social Science and epidemiology</b>
<b>311</b> OC 60	A less recent diagnosis is associated with local transmission clusters among HIV-1 primary infections in Rome	Lavinia Fabeni, Roma
16.20-16.30		
<b>267</b> OC 61	High HIV Prevalence following Screening of Subjects with HIV Indicator Conditions in a Hospital Setting	Camilla Tincati, Milano
16.30-16.40		

## Elenco Oral Communications

ID	Title	Presenting Author
40 16.40-16.50	<b>OC 62</b> The cascade of care as tool to promote a more effective city-wide program against HIV/AIDS	Franco Maggiolo, Bergamo
25 16.50-17.00	<b>OC 63</b> Causes and incidence of hospitalization in patients enrolled in the ICONA cohort	Silvia Nozza, Milano
61 17.00-17.10	<b>OC 64</b> The 4th Ninety in the 4th Decade	Amalia Bove, Roma
326 17.10-17.20	<b>OC 65</b> General Practitioners and PLWH: what do patients think?	Serena Rita Bruno, Foggia
<b>16/10/2020</b>	<b>17.20 - 18.20 Pharmacology</b>	
17.20-17.30	The importance of deprescribing in HIV	J. Moltò, Badalona
75 17.30-17.40	<b>OC 66</b> Use of direct oral anticoagulants in people living with HIV: a single-center experience	Cristina Gervasoni, Milano
2 17.40-17.50	<b>OC 67</b> Pharmacokinetics of once-daily doravirine over 72 hours following drug cessation	Maria Mazzitelli, Catanzaro
241 17.50-18.00	<b>OC 68</b> Inflammation Affects Antiretrovirals Plasma and Intracellular Exposure	Micol Ferrara, Torino
255 18.00-18.10	<b>OC 69</b> Bictegravir plasma and intracellular pharmacokinetics in in the clinical setting	Micol Ferrara, Torino
171 18.10-18.20	<b>OC 70</b> Generic pre-exposure prophylaxis formulations: a comparison of tenofovir trough concentrations	Dario Cattaneo, Milano